The autoimmune targets in IPEX are dominated by gut epithelial proteins
To the Editor:
Regulatory T (Treg) cells play a key role in immune system homeostasis by suppressing detrimental immune responses against self-proteins, in particular in the intestine. 1 Patients with mutations in the gene FOXP3 display a severe defect of Tregcell function that results in IPEX syndrome (OMIM 304790) characterized by impaired immune tolerance and multiorgan autoimmunity. Dermatitis, type 1 diabetes, and in particular autoimmune enteropathy are hallmarks of the syndrome. Intestinal Treg cells normally suppress immune responses against harmless dietary antigens and commensal microorganisms, but the intestinal self-proteins that are guarded by Treg cells have not yet been fully identified. 2 Patients with IPEX and enteritis typically harbor autoantibodies against harmonin (USH1C) and villin, which are structural proteins predominantly expressed in brush border epithelia of the intestine and renal tubules. 3, 4 Autoantibodies against glutamate decarboxylase-65 (GAD-65, GAD2), 5 which is a marker for islet cell autoimmunity in type 1 diabetes, have been detected in patients with IPEX already in their first week of life. These studies suggest that the autoimmune pathogenesis of IPEX involves a humoral response that can be exploited for identifying the immune targets. 6 Hitherto, no studies have been undertaken to characterize autoantigens in IPEX syndrome in a comprehensive way. Here, we sought to identify the autoantibody targets in patients with IPEX on a broad scale to gain better understanding of the autoimmune manifestations of IPEX and insights to peripheral tolerance mechanisms mediated by Treg cells.
We used panels of more than 9000 human proteins to characterize autoantibody targets in 14 patients with IPEX and 24 healthy controls (detailed methodology and additional tables/ figures are available in this article's Online Repository at www. jacionline.org). In total 20 proteins clearly stood out as patientspecific autoantigens (Fig 1; see Table E1 in this article's Online Repository at www.jacionline.org). Among them, the 3 previously known IPEX autoantigens included in the panels were all present: harmonin, 3 a-IFN, 7 and GAD-65, 5 verifying a reliable detection of autoantibodies (Fig 1, C, and Fig E1) .
Interestingly, the new autoantigens showed predominant expression in tissues typically affected in patients with IPEX, in particular in the intestinal epithelium. In the brush border of enterocytes, ANKS4B and harmonin form a complex that anchors transmembrane links reaching between the tips of microvilli to the enterocyte cytoskeleton (Fig 2, A) . Competition assays revealed no autoantibody cross-reactivity, suggesting that harmonin and ANKS4B were independent autoantigens (see Fig E2 in this article's Online Repository at www.jacionline.org). Another novel autoantigen, ACSL5, is primarily expressed in the small intestine, where it regulates the enterocyte proliferation along the crypt-villus axis. The protein with the strongest autoantibody signal in the protein array data, HNF4A, is a nuclear receptor with an expression pattern that closely follows that of harmonin and ANKS4B. HNF4A has important functions in differentiation of intestinal and renal epithelia. To validate the proteome-wide autoantibody data with an independent method, we developed radio-ligand binding assays for a subset of the new candidate autoantigens ANKS4B, HNF4A, PPARG, and RXRA, as well as for 3 established autoantigens: GAD-65, harmonin, and villin. We extended the group of patients with IPEX with 3 additional patients in the validation experiments (n 5 17). To better evaluate the clinical specificity, we also included a larger group of healthy subjects (n 5 75) and sera from other autoimmune and inflammatory diseases: inflammatory bowel disease (n 5 20), autoimmune polyendocrine syndrome (APS) type 1 (n 5 20), and APS-2 (n 5 40). The novel autoantigens ANKS4B, HNF4A, PPARG, and RXRA were all confirmed in the radio-ligand binding assay and showed high specificity for IPEX in the investigated clinical material (see Figs E3 and E4 in this article's Online Repository at www.jacionline.org).
Among the 16 patients with IPEX and enteropathy, 11 of 16 (69%) were positive for autoantibodies against harmonin, 9 of 16 (56%) against ANKS4B, 7 of 16 (44%) against HFN4A, and 8 of 14 (57%) against ACSL5 (ACSL5 autoantibody data were available only for the discovery case group) (Fig 2, B) . Hence, 11 of 16 patients (69%) displayed autoantibodies against 1 or more autoantigens in the intestinal epithelium. Although the number of patients without enteropathy was too small to assess any statistical associations with specific autoantibodies, we noted that the only patient without enteropathy was negative for all the intestinal autoantibodies. Two patients were negative for all investigated autoantibodies. Both these patients displayed clinical manifestations and mutations in FOXP3 typical for IPEX (Table E1) .
Besides HNF4A, our list of top 20 targets from the protein array contained 10 additional nuclear receptors, all with highly correlated results. Because nuclear receptors share an evolutionary template featuring a highly conserved DNA-binding domain and a moderately conserved ligand-binding domain, we performed competition assays to test for cross-reactivity. Focusing on a subset of the nuclear receptor autoantigens, HNF4A, RXRA, and PPARG, we could demonstrate a crossreactivity between these autoantigens (see Fig E5 in this article's Online Repository at www.jacionline.org). Hence, the nuclear receptor autoantibodies were specific for a subset of nuclear receptors, but cross-reactive within this subset. Investigations of truncated nuclear receptor protein in the array indicated that the nuclear receptor autoantibodies targeted a shared epitope in the ligand-binding domain.
IPEX can rapidly become fatal if not aggressively treated. Although immunosuppressive therapy can give transient or partial improvement of disease symptoms, allogenic hematopoietic stem cell transplantation (HSCT) offers the only possibility of cure. By investigating consecutive samples from patients with IPEX taken before and after treatment, we found that autoantibodies remained detectable following immunosuppressive treatment with rapamycin but completely disappeared 1.5 years following successful HSCT (see Fig Although this is by far the most comprehensive study of autoantibody targets in IPEX, less than half of the protein coding genes were covered in our screen. For instance, the previously identified skin autoantigen in IPEX, keratin 14, 8 was not present in the investigated panel.
In summary, we have identified intestinal self-antigens that are implicated in the enteropathy of IPEX, which may advance the understanding of FOXP3-dependent Treg cells in controlling immune tolerance toward self-antigens in the gut. Mast cells (MCs) are abundant in skin that interfaces with the outside environment. MC precursors migrate to the skin during embryogenesis, and they develop under the influence of tissuespecific factors.
1 Although they have a well-established MC role in allergy, their relationship with hair is less understood. In fact, MCs are present in lesions of patients with alopecia areata, 2 and patients with alopecia areata frequently report itching during the activity phase of the disease. Interestingly, MC hyperplasia is a striking feature of hairless mice discovered by Fujii et al. 3 However, the mechanisms of this MC hyperplasia in hairless mice were not investigated further. Genetically, hairless mice are characterized by the absence of the hairless gene (Hr).
Hr is highly expressed in both human and mouse skin. Degrading Hr mRNA results in transformation from hairy skin into hairless skin. However, MC hyperplasia observed in the skin of hairless mice is not a distinctive feature of Hr mutant mice. In fact, an increased number of MCs in the skin was reported in different strains of hairless mice, including BALB/c nude mice, a strain of mice with the absence of thymus but a normal Hr gene. 4 Moreover, a previous study noted that MC numbers increased during the period when hair regeneration enters late anagen, suggesting that MC numbers can oscillate with environmental changes during the hair growth cycle.
5
One main characteristic of absent hair is thought to be the physical feature of habitats for a distinctive microbiome on the skin surface. Our group recently demonstrated that the microbiome induces MC maturation in the skin because it induces stem cell factor (SCF) production in keratinocytes, which is essential for MC survival. 6, 7 Therefore we hypothesized that changes in the skin microbiome caused by hair loss could be an important factor in increasing the number of MCs present in the skin of hairless mice.
We first generated C57 HR (C57BL/6J hairless) mice, which present with MC hyperplasia and hairless skin compared with the hairy skin of C57 wild-type (WT) mice. We evaluated the number of MCs in the skin and found a significant increase in MC numbers by counting MCs from 5 tissue sections of 4 mice per group. The average number of MCs in the C57 WT group was 24 6 4/mm 2 , whereas that in C57 HR mice was 83 6 16/mm 2 ( Fig  1, A-C) . Interestingly, C57 HR newborn mice have normal first fur, but pups start losing hair from the 14th day after birth.
Therefore, to determine whether the discontinued hair cycle affects MCs, we verified MC numbers in hairy skin from 1-weekold (1WO) C57 HR mice by means of avidin staining. As expected, we found that the average number of MCs in the 1WO C57 HR group was 51 6 3 MCs/mm 2 , which was less than the average 85 6 7 MCs/mm 2 in adult skin of C57 HR mice (Fig 1,  D-F , and see Fig E1 in this article's Online Repository at www. jacionline.org). When we compared 1WO C57 WT mice with 8-week-old mice, they had slightly fewer MCs. However, 1-week-old C57 mice WT already had a significantly lower number of MCs when compared with the 1WO C57 HR mice. This difference could be considered the genetic component of HR mice for MC numbers.
To assess the function of MCs in C57 HR mice, we examined MC-specific enzyme activities, such as chymase and tryptase. Immunofluorescent staining showed that there was an increased expression of chymase in C57 HR mice that correlated with the accumulation of excessive MCs in their dermis (Fig 1, G-J) . A remarkably high b 2 -tryptase (Tpsb2) expression was found in the skin of C57 HR but not C57 WT mice (Fig 1, K) . Likewise, a strikingly high expression of trypsin-like activity was found when we performed fluorometric analysis (Fig 1, L) . In addition, we evaluated MC function by measuring the diameter increase in skin edema using Compound 48/80 (Sigma, St Louis, Mo). We found that C57 HR mice had a much bigger edema area than C57 WT mice, which indicated increased release of MC mediators (Fig 1, M) .
We also measured MC reactivity using passive cutaneous anaphylaxis. A larger edema area was observed in C57 HR mice, suggesting MCs were activated by IgE (Fig 1, N) . These results demonstrate that MCs in skin of C57 HR mice are functioning normally.
Given that our laboratory previously demonstrated that MC maturation and migration can be promoted by using skin commensal gram-positive bacteria through the Toll-like receptor 2 (TLR2)-SCF pathway in keratinocytes, 6, 7 we investigated the composition of the skin microbiome in C57 HR and C57 WT mice. Skin microbiome composition was assessed by using 16S rRNA sequencing performed on 14 samples, including 8 C57 WT mice, 4 C57 HR mice, and two 1-week-old C57 HR mice.
METHODS

Clinical subjects
Patients with IPEX were included from Italy, the Unites States, and Germany. All patients fulfilled clinical diagnostic criteria for IPEX, requiring a disruptive FOXP3 mutation and manifestation of enteropathy and/or endocrinopathies. Blood donors not known to suffer from autoimmune disease were included as healthy controls, both in the discovery (n 5 24) and in the validation control (n 5 75) groups. The validation control groups also included additional subjects with autoimmune diseases: 20 subjects with autoimmune polyendocrine syndrome type 1 (APS1); 20 subjects with APS2 with type 1 diabetes; 20 subjects with APS2 without type 1 diabetes; 10 subjects with ulcerative colitis; and 10 subjects with Crohn disease.
Protein array screening
Protein arrays containing more than 9000 full-length human proteins (ProtoArray v5.1, PAH05251020, ThermoFisher, Waltham, Mass) were used to study autoantibodies in serum samples diluted 1:2000. The arrays were probed according to the manufacturer's protocol using the recommended reagents: (PA055, ThermoFisher), Alexa Fluor 647 goat antihuman IgG (A21445, ThermoFisher), Dylight 550 goat anti-GST (#DY550011-13-001, Cayman Chemicals, Ann Arbor, Mich), and the LuxScan HT24 (BioCapital) micro-array scanner.
Radio-ligand binding assay
Autoantibodies were measured by immunoprecipitation of antigens radiolabeled with 35 S-methionine. Complementary DNA clones were purchased from Origene and subcloned into pTNT or Sp64 expression vectors (L5610, Promega, Madison, Wis), which were used for transcription and translation in vitro (Promega TNT Systems): USH1C SC336653 (NM_001297764), ANKS4B SC306281 (NM_145865), HNF4A SC307232 (NM_178849), PPARG SC322218 (NM_138712), RXRA SC118299 (NM_002957), VIL1 SC123608 (BC_017303). Immunoprecipitation was conducted in 96-well filtration plates (Millipore, Burlington, Mass). Serum samples (2.5 mL) were incubated overnight at 48C with 30'000 cpm of radiolabeled protein. Immune complexes were captured with protein A Sepharose (Protein A Sepharose 4 Fast Flow, GE Healthcare, Chicago, Ill) during a 45-minute incubation. After 10 washing steps, radioactive decay was measured in a beta counter (1450 Microbeta Triplex, Wallac). All serum samples were tested in duplicate in separate wells. BSA (4%) was included in each plate to serve as a negative standard. For each antigen, a selected IPEX or APS1 patient serum was included in all 96-well plates to serve as a positive standard for index calculation. Autoantibody indices were calculated according to the following: (sample value 2 negative standard value) O (positive standard value 2 negative standard value) 3 100. The upper limits of the normal range were defined as an index value of 5 SDs above the mean of the healthy controls.
Statistics
Quantile normalization was applied to reduce the effects of technical variation between different protein array experiments. E1 Protein targets affected by printing contaminations were identified using a previously described approach and removed (n 5 4). E2 Protein targets were sorted by their difference between cases and controls. For each protein, the strongest signal intensity in the control group was subtracted from the second to strongest patient signal intensity. Thereby, targets with elevated signal in 2 or more patients could be selected. Clusters of autoantigens were identified by correlation.
Study approval
All study subjects gave their informed consent for participation in accordance with their local institutional review boards (IRBs). The study was performed in accordance with the Declaration of Helsinki and approved by the local ethics committees (2008/296-31/2 and 2016/2553-31/2 by Stockholm, UP 00-052 by Uppsala, IRB protocol TIGET02 and TIGET06 by Ospedale San Raffaele, and IRB protocol 34131 by Stanford University).
Protein annotation
The STRING database was used for functional enrichment analysis of PFAM protein domains, and GO-terms describing biological processes. E3 Protein primary structures retrieved from the array manufacturer were aligned with Clustal omega.
E4,E5 Mutations were annotated using the gene transcript hg19_knownGene_uc004dnf. 4, chrX:49106897-49121288 .
Protein expression levels and immunohistochemistry
RNA-Seq data from the GTEx database were used to investigate protein expression. E6-E8 To detail the tissue distribution of novel autoantigens, we investigated immunohistochemical stainings retrieved from the Human Protein Atlas.
E9,E10
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FIG E3.
Verification of novel autoantigens with independent methods in extended case and control groups. The previously identified autoantigens harmonin (USH1C) and glutamate decarboxylase-65 (GAD2), and the novel candidate autoantigens harmonin-interacting protein (ANKS4B), HNF4A, RXRA, and PPARG, showed elevated signals in the protein array screening (A), and were validated using radio-ligand binding assays (B). All 14 patients with IPEX from the discovery screen and 3 new patients with IPEX were assessed. Additional control subjects were included: 75 healthy blood donors; 20 subjects with APS1; 40 subjects with APS2 (10 with and 10 without type 1 diabetes mellitus); and 20 subjects with inflammatory bowel disease (10 with ulcerative colitis and 10 with Crohn disease). 5 14) . B-D, Competition assays were used to study autoantibody cross-reactivity. Radiolabeled nuclear receptor autoantigens (*) were competed against unlabeled protein of the same autoantigen species, other nuclear receptor autoantigens, and ANKS4B as a negative control. The x-axes denote ratios of labeled to unlabeled protein. E, The heatmap displays signal intensities for the nuclear receptors in the protein array ordered by sequence similarity. The 4 patients with IPEX with the strongest signals for nuclear receptor autoantigens are included. The strongest signal among healthy controls has been summarized in 1 column, to illustrate that all healthy controls had weak signals for all nuclear receptors. RLBA, Radioligand binding assay. 
